Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
InflaRx NV Market Cap
Based on ratings from 5 stock analysts, the InflaRx NV stock price is expected to increase by 235.09% in 12 months. This is calculated by using the average 12-month stock price forecast for InflaRx NV. The lowest target is $5.27629 and the highest is $13.49017. Please note analyst price targets are not guaranteed and could be missed completely.
IFRX is a stock in Healthcare which has been forecasted to be worth $8.61182 as an average. On the higher end, the forecast price is $13.49017 USD by from and on the lower end IFRX is forecasted to be $5.27629 by from .
These are the latest 20 analyst ratings of IFRX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Edward White HC Wainwright & Co. | Buy | $8 | Reiterates | Nov 15, 2024 |
| Edward White HC Wainwright & Co. | Buy | $8 | Reiterates | Nov 11, 2024 |
| Edward White HC Wainwright & Co. | Buy | $8 | Reiterates | Sep 25, 2024 |
| Edward White HC Wainwright & Co. | Buy | $8 | Reiterates | Jun 24, 2024 |
| Edward White HC Wainwright & Co. | Buy | $8 | Reiterates | Jun 6, 2024 |
| Edward White HC Wainwright & Co. | Buy | $8 | Reiterates | May 9, 2024 |
| Edward White HC Wainwright & Co. | Buy | $8 | Reiterates | Mar 22, 2024 |
| Edward White HC Wainwright & Co. | Buy | $8 | Maintains | Jan 25, 2024 |
| Steven Seedhouse Raymond James | Strong Buy | $19 | Maintains | Nov 2, 2023 |
| Edward White HC Wainwright & Co. | Buy | $9 | Reiterates | Sep 12, 2023 |
HC Wainwright & Co. | Buy | Reiterates | Aug 31, 2023 | |
HC Wainwright & Co. | Buy | Reiterates | Aug 11, 2023 | |
| Steven Seedhouse Raymond James | Strong Buy | $21 | Maintains | May 12, 2023 |
| Edward White HC Wainwright & Co. | Buy | $9 | Reiterates | May 12, 2023 |
| Edward White HC Wainwright & Co. | Buy | $9 | Maintains | Apr 21, 2023 |
| Steven Seedhouse Raymond James | Strong Buy | $25 | Maintains | Apr 6, 2023 |
| Yatin Suneja Guggenheim | Buy | $8 | Upgrade | Apr 5, 2023 |
| Sam Slutsky LifeSci Capital | Outperform | Upgrade | Apr 5, 2023 | |
| Edward White HC Wainwright & Co. | Buy | $10 | Reiterates | Apr 5, 2023 |
| Edward White HC Wainwright & Co. | Buy | $6 | Reiterates | Mar 23, 2023 |
When did it IPO
2017
Staff Count
62
Country
Germany
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Niels C. Riedemann M.D., Ph.D.
Market Cap
$154.3M
In 2023, IFRX generated $63,089 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that IFRX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Fri, 15 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - InflaRx N.V. received a positive CHMP recommendation for marketing authorization of GOHIBIC for treating COVID-19-related ARDS in patients on mechanical ventilation. Approval expected soon.
Why It Matters - Positive CHMP opinion for GOHIBIC boosts InflaRx's potential revenue from EU sales, signaling confidence in its product pipeline and enhancing investor sentiment.
Fri, 08 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - InflaRx N.V. announced its financial results for Q3 and the nine months ending September 30, 2024, along with an operational update, focusing on anti-inflammatory therapeutics.
Why It Matters - InflaRx's financial results and updates on its anti-inflammatory therapeutics can influence stock performance and investor sentiment regarding its growth potential and market position.
Fri, 08 Nov 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - InflaRx N.V. (IFRX) reported a quarterly loss of $0.33 per share, which is worse than the Zacks Consensus Estimate of a loss of $0.27.
Why It Matters - InflaRx's larger-than-expected quarterly loss may indicate financial instability, potentially impacting investor confidence and stock performance.
Wed, 25 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - InflaRx N.V. (Nasdaq: IFRX) presented a post hoc analysis of its vilobelimab for hidradenitis suppurativa at the EADV Congress in Amsterdam, September 25-28, 2024.
Why It Matters - The presentation of positive data on vilobelimab could boost InflaRx's stock value, indicating potential for market approval and increased investor confidence in its therapeutic pipeline.
Tue, 24 Sep 2024
Sentiment - NEUTRAL
Source - 24/7 Wall Street
Summary - Penny stocks can yield high returns for investors but carry significant risks.
Why It Matters - Penny stocks offer high return potential but come with significant risk, influencing investor strategies and market volatility.
Tue, 03 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - InflaRx N.V. (Nasdaq: IFRX) presented preclinical data for its oral C5aR inhibitor, INF904, at the 2024 EMCHD in Lübeck, Germany, from September 2-6, 2024.
Why It Matters - Preclinical data on INF904 may indicate progress in anti-inflammatory treatments, potentially influencing stock performance and market confidence in InflaRx's future innovations.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
